WebOct 21, 2015 · Petri MA, et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with seropositive SLE: combined efficacy results from the phase 3 BLISS-52 and -76 studies. Arthritis & Rheumatism 2010; 62(Suppl 10): 452. View Article Google Scholar 25. WebAtacicept as the inhibitor of BLyS and APRIL thus has a broader biological effect than belimumab alone and more clearly blocks B-cell maturation and B-cell and plasma cell …
BLyS-Specific Inhibitors - GoodRx
WebNov 30, 2011 · It is a specific inhibitor of the soluble B-lymphocyte stimulator (BLyS) cytokine, which has been implicated in the pathogenesis of systemic lupus … Belimumab, sold under the brand name Benlysta, is a human monoclonal antibody that inhibits B-cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS). It is approved in the United States and Canada, and the European Union to treat systemic lupus erythematosus and lupus nephritis. The most … See more Belimumab is indicated for the treatment of active systemic lupus erythematosus and active lupus nephritis. See more B lymphocytes (B cells), which are part of the normal immune response, are also responsible for the over-aggressive response seen in autoimmune diseases like systemic lupus erythematosus. B cells develop in the bone marrow and continue to mature peripherally … See more Legal status Under the brand name Benlysta, belimumab received FDA approval for the treatment of systemic lupus erythematosus on 9 … See more • "Belimumab". Drug Information Portal. U.S. National Library of Medicine. See more Common adverse effects reported with belimumab include nausea, diarrhea, and fever, as well as hypersensitivity and infusion-site reactions, which were severe in 0.9% of patients. … See more B-cell activating factor is a naturally occurring protein that was discovered by researchers from National Jewish Health (previously the National Jewish Medical and Research … See more Blisibimod, an inhibitor of both soluble and membrane-bound BAFF, has demonstrated similar reductions of B cells in clinical trials and is being investigated in a Phase II clinical … See more gerard reilly solicitor
Belimumab: A BLyS-Specific Inhibitor for the Treatment of …
WebNational Center for Biotechnology Information WebJul 27, 2024 · BENLYSTA, a BLyS-specific inhibitor, is a human monoclonal antibody that binds to soluble BLyS. BENLYSTA does not bind B cells directly. By binding BLyS, BENLYSTA inhibits the survival of … WebThe B lymphocyte stimulator (BLyS)-A PRoliferation-Inducing Ligand (APRIL) signaling pathway has an important role in the selection, maturation and survival of B cells and … gerard residential treatment